

## Committee minutes

### Termination of Pregnancy Committee meeting 1

**Date:** 1&2/11/2017

**Location:** RCOG, London

**Minutes:** Confirmed



#### Day 1

<b>Committee members present:</b>	
Iain Cameron (Chair)	(Present for notes 1 – 14)
Sharon Cameron (Topic adviser)	(Present for notes 1 – 14)
Joanne Fletcher	(Present for notes 1 – 14)
Patricia Lohr	(Present for notes 1 – 14)
Jonathan Lord	(Present for notes 1 – 14)
Michael Nevill	(Present for notes 1 – 14)
Kate Randall	(Present for notes 1 – 14)
Peter Taylor	(Present for notes 1 – 14)

<b>In attendance:</b>		
Emma Chambers	NICE Public Involvement Adviser	(Present for notes 1 – 13)
Nick Staples	NICE Guideline Commissioning Manager	(Present for notes 1 – 6)
Alex Bates	NGA Health Economist	(Present for notes 1 - 13)
Angela Bennett	NGA Guideline Lead	(Present for notes 1 – 14)
Melanie Davies	NGA Clinical Advisor	(Present for notes 1 – 8)
Jennifer Francis	NGA Project Administrator	(Present for notes 1 – 4)
Elise Hasler	NGA Information Scientist	(Present for notes 1 – 14)
Eleanor Howat	NGA Project Manager	(Present for notes 1 – 14)
Mia Schmidt-Hansen	NGA Senior Systematic Reviewer	(Present for notes 14 only)
Kelly Williams	NGA Systematic Reviewer	(Present for notes 1 – 14)

<b>Apologies:</b>	
Huayi Huang	NGA Systematic Reviewer

## Committee minutes

Laura O'Shea

NGA Systematic Reviewer

### 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the first meeting on Termination of Pregnancy. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: committee induction, considering the questions in the guideline scope, and preparing review question protocols.

### Introductions

The committee and other attendees introduced themselves.

### 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was termination of pregnancy.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Iain Cameron	Dean of the Faculty of Medicine, University of Southampton	As Dean of the Faculty of Medicine, University of Southampton, I have overall responsibility for the Faculty's research portfolio and its associated funding. There is industry involvement in basic research and clinical trials run by the Faculty, including provision of funding for the research itself and some staff posts. As Dean I do not normally have direct involvement in negotiating this funding or deciding how it is spent. [declared at recruitment]	Non-personal, financial, non-specific.	Declare and participate
Iain Cameron	Dean of the Faculty of Medicine, University of Southampton	I have previously acted as Principal Investigator on commercially-funded studies in reproductive medicine, but have had no direct involvement for over five years. [declared at recruitment]	Non-personal, financial, non-specific	Declare and participate

## Committee minutes

Iain Cameron	Dean of the Faculty of Medicine, University of Southampton	I am remunerated for 2.5 days monthly as a Non-Executive Director of University Hospital of Southampton NHS Foundation Trust [declared at recruitment]	Personal, financial, non-specific.	Declare and participate
Sharon Cameron	Clinical Lead for Sexual and Reproductive Health services, NHS Lothian	I received funding (conference fees and travel) to attend the conference of the International Association of Medical Regulators in Melbourne in September 2016 [declared at recruitment]	Personal, financial, non-specific.	Declare and participate
Sharon Cameron	Clinical Lead for Sexual and Reproductive Health services, NHS Lothian	Investigator Initiated research funding from Pfizer, to conduct research on feasibility and acceptability of provision of repeat injections of progestogen only injectable contraception from community pharmacists (ended 2016) [declared at recruitment]	Non-personal financial non-specific	Declare and participate
Sharon Cameron	Clinical Lead for Sexual and Reproductive Health services, NHS Lothian	Received an honorarium from Exelgyn for attending an advisory board to work on developing educational information for healthcare professionals on abortion care e.g. FAQs and answer booklets. Activity ended November 2016. [declared at recruitment]	Personal, financial, specific	Declare and withdrawn from discussion on questions about medical termination of pregnancy until November 2017
Joanne Fletcher	Nurse Consultant Gynaecology, Sheffield teaching hospitals NHS foundation trust, Senior Visiting lecturer, Sheffield University	Manual vacuum aspiration trainer for Durbin Sexual Health Supplies [declared at recruitment] Update on 31.10.2017 training event at Association of Early Pregnancy Units annual scientific conference, x 2 lecturers - travel expenses received, fee was waived Update on 1.11.2017 No longer accepting payment from Durbin during guideline development. Date of last payment November 2016.	Personal, financial, specific	Declare and withdraw from discussions of review questions (2.8) that include manual vacuum aspiration until November 2017.
Joanne	Nurse	Co-founder of and co-chair of	Personal,	Declare

## Committee minutes

Fletcher	Consultant Gynaecology, Sheffield teaching hospitals NHS foundation trust, Senior Visiting lecturer, Sheffield University	British Society of Abortion care providers [declared at recruitment]	non-financial, specific	and participate
Joanne Fletcher	Nurse Consultant Gynaecology, Sheffield teaching hospitals NHS foundation trust, Senior Visiting lecturer, Sheffield University	Immediate past President and Hon. secretary of the Sexuality & Sexual Council, Royal Society of Medicine [declared at recruitment]	Personal, non-financial, non-specific	Declare and participate
Joanne Fletcher	Nurse Consultant Gynaecology, Sheffield teaching hospitals NHS foundation trust, Senior Visiting lecturer, Sheffield University	Scientific committee member, Association of Early pregnancy units [declared at recruitment]	Personal, non-financial, non-specific	Declare and participate
Joanne Fletcher	Nurse Consultant Gynaecology, Sheffield teaching hospitals NHS foundation trust, Senior Visiting lecturer, Sheffield University	Manual Vacuum aspiration trainer for Royal College of Obstetrics and Gynaecology (unpaid). Travel expenses paid, no remuneration. [declared at recruitment]	Personal, non-financial, specific	Declare and participate
Joanne Fletcher	Nurse Consultant Gynaecology, Sheffield teaching hospitals NHS	Chief investigator for local study: A comparison of termination of pregnancy procedures: Patient choice, emotional impact and satisfaction with care [declared at recruitment]	Non-personal, financial, specific	Declare and participate

## Committee minutes

	foundation trust, Senior Visiting lecturer, Sheffield University			
Joanne Fletcher	Nurse Consultant Gynaecology, Sheffield teaching hospitals NHS foundation trust, Senior Visiting lecturer, Sheffield University	Principle Investigator for National study: VESPA (variations in the organizations of early pregnancy assessment units in the UK and their effects on clinical, service and patient centered outcomes) [declared at recruitment]	Non-personal, financial, non-specific	Declare and participate
Joanne Fletcher	Nurse Consultant Gynaecology, Sheffield teaching hospitals NHS foundation trust, Senior Visiting lecturer, Sheffield University	Principle investigator for National study: PRISM (progesterone in spontaneous miscarriage) – [declared at recruitment]	Non-personal, financial, non-specific	Declare and participate
Joanne Fletcher	Nurse Consultant Gynaecology, Sheffield teaching hospitals NHS foundation trust, Senior Visiting lecturer, Sheffield University	Principle investigator for local study (in collaboration with Centre for Stem cell Biology, University of Sheffield): Derivation of Human Ear Stem cells [declared at recruitment]	Non-personal, financial, non-specific	Declare and participate
Patricia Lohr	Medical Director, British Pregnancy Advisory Service (BPAS)	Research funding from HRA Pharma (makers of emergency contraceptive ellaOne (ulipristal acetate). Grant ended in December 2016 - organizational support provided, no personal financial support provided in the grant. [declared at recruitment]	Non-personal, financial, non-specific	Declare and participate
Patricia Lohr	Medical Director, British	Research funding from Medicem (makers of Dilapan osmotic cervical dilators). Grant ended in	Non-personal financial,	Declare and participate

## Committee minutes

	Pregnancy Advisory Service (BPAS)	December 2016 – organisational support provided, no personal financial support provided for in the grant [declared at recruitment]	specific	
Patricia Lohr	Medical Director, British Pregnancy Advisory Service (BPAS)	Project Supervisor/Co-investigator (Principal Investigator Jennifer K. Hsia, Family Planning fellow at University of California, Davis) - Early Medical Abortion Between 64 and 70 Days Gestation in the UK: Effectiveness of an Interval Misoprostol Protocol. Funder: Anonymous. Funding received to support BPAS Research Nurse, no personal financial support. [declared at recruitment]	Non personal, financial, specific	Declare and participate
Patricia Lohr	Medical Director, British Pregnancy Advisory Service (BPAS)	Co-investigator/applicant: Improving the Acceptability and Uptake of Long acting Reversible Contraception to Young Women. Co-investigator (Principal Investigator Judith Stephenson). Funder: NIHR/HTA. Neither BPAS nor I receive funding to assist in this project. [declared at recruitment]	Non-personal, financial non-specific	Declare and participate
Patricia Lohr	Medical Director, British Pregnancy Advisory Service (BPAS)	Co-investigator/applicant: Human Developmental Biology Resource (HDBR): an embryonic and fetal tissue bank for the new genetics technologies. Co-investigator (Principal Investigators Andrew Copp, Steve Robson). Funder: MRC-Wellcome. Neither BPAS nor I receive funding to assist in this project. As a Co-investigator I am a member of the Joint Steering Committee. [declared at recruitment]	Non-personal, financial non-specific	Declare and participate
Patricia Lohr	Medical Director, British Pregnancy Advisory Service (BPAS)	Course organiser for RCOG/FSRH/BSACP Manual Vacuum Aspiration training days which are delivered twice a year. Durbin, a supplier of medical devices, provides the aspirators and cannulas used during the practical sessions. I receive no financial payment for organising or leading the	Personal, non-financial, specific	Declare and participate

## Committee minutes

		course. [declared at recruitment]		
Patricia Lohr	Medical Director, British Pregnancy Advisory Service (BPAS)	Treasurer, British Society of Abortion Care Providers (RCOG specialist society) [declared at recruitment]	Personal, non-financial, specific	Declare and participate
Patricia Lohr	Medical Director, British Pregnancy Advisory Service (BPAS)	Member, Doctors for a Women's Choice on Abortion (advocacy organisation) [declared at recruitment]	Personal, non-financial, specific	Declare and participate
Patricia Lohr	Medical Director, British Pregnancy Advisory Service (BPAS)	<p>Publications in last 12 months:</p> <ol style="list-style-type: none"> <li>1. Gerdts C, DeZordo S, Mishtal J, Barr-Walker J, <b>Lohr PA</b>. Experiences of women who travel to England for abortions: an exploratory pilot study. <i>Eur J Contracept Reprod Health Care</i>. 2016 Aug 19:1-7. [Epub ahead of print]</li> <li>2. van den Berg GF, Picavet C, Hoopman R, <b>Lohr PA</b>, Op de Coul EL. Chlamydia screening and prophylactic treatment in termination of pregnancy clinics in the Netherlands and Great Britain: a qualitative study. <i>Eur J Contracept Reprod Health Care</i>. 2016:1-7. [Epub ahead of print]</li> <li>3. Aiken A, <b>Lohr PA</b>, Aiken CE, Forsyth T, Trussell J. Contraceptive method preferences and provision after termination of pregnancy: a population-based analysis of women obtaining care with the British Pregnancy Advisory Service. <i>BJOG</i>. 2016 Nov 14. doi: 10.1111/1471-0528.14413. [Epub ahead of print]</li> <li>4. ESHRE Capri Workshop Group. Induced abortion. <i>Hum Reprod</i>. 2017;32(6):1160-1169.</li> <li>5. Cameron S, <b>Lohr PA</b>, Ingham R. Abortion terminology: views of women seeking abortion in Britain. <i>J Fam Plann Reprod Health Care</i>. 2017 Jul</li> </ol>	Personal, non-financial, specific	Declare and participate

## Committee minutes

		11. pii: jfprhc-2016-101631. doi: 10.1136/jfprhc-2016-101631. [Epub ahead of print] [declared at recruitment]		
Patricia Lohr	Medical Director, British Pregnancy Advisory Service (BPAS)	<p>Past publications that may be considered by the committee in relation to abortion:</p> <p><b>1. Lohr PA</b>, Reeves MF, Hayes JL, Harwood B, Creinin MD. Oral mifepristone and buccal misoprostol administered simultaneously for abortion: a pilot study. <i>Contraception</i>. 2007;76(3):215-20.</p> <p><b>2. Lohr PA</b>, Hayes JL, Gemzell-Danielsson K. Surgical versus medical methods for second trimester induced abortion. <i>Cochrane Database of Systematic Reviews</i> 2008, Issue 1. Art. No.: CD006714. DOI: 10.1002/14651858.CD006714.pub2.</p> <p>3. Reeves MF, <b>Lohr PA</b>, Hayes JA, Harwood BJ, Creinin MD. Doxycycline serum levels at the time of dilation and evacuation with two dosing regimens. <i>Contraception</i>. 2009;70(2):129-133.</p> <p>4. Reeves MF, Fox MC, <b>Lohr PA</b>, Creinin MD. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. <i>Ultrasound Obstet Gynecol</i>. 2009;34:104-9.</p> <p><b>5. Lohr PA</b>, Wade J, Riley L, Fitzgibbon A, Furedi A. Women's opinions on the home management of early medical abortion in the UK. <i>J Fam Plann Reprod Health Care</i>. 2010;36(1):21-5.</p> <p><b>6. Lohr PA</b>, Reeves MF, Creinin MD. A comparison of transabdominal and transvaginal ultrasonography for determination of gestational age</p>	Personal, non-financial, specific	Declare and participate



## Committee minutes

		<p>and clinical outcomes in women undergoing early medical abortion. Contraception. 2010;81(3):240-4.</p> <p>7. Kapp N, <b>Lohr PA</b>, Ngo TD, Hayes JL. Cervical preparation for first trimester surgical abortion. Cochrane Database of Systematic Reviews 2010, Issue 2. Art. No.:CD007207. DOI: 10.1002/14651858.CD007207.pub2.</p> <p>8. Lyus R, <b>Lohr PA</b>, Taylor J, Morroni C. Outcomes with same-day cervical preparation with Dilapan-S osmotic dilators and vaginal misoprostol before dilatation and evacuation at 18 to 21+6 weeks' gestation. Contraception. 2013;87:71-5.</p> <p>9. Bracken H, <b>Lohr PA</b>, Taylor J, Morroni C, Winikoff B. RU OK? The acceptability and feasibility of remote technologies for follow-up after early medical abortion. Contraception. 2014;90:29-35.</p> <p>10. Fisher J, <b>Lohr PA</b>, Lafarge C, Robson SC. Termination for fetal anomaly: Are women in England given a choice of method? J Obstet Gynaecol. 2014 Jul 24:1-5. [Epub ahead of print]</p> <p>11. Myers AJ, <b>Lohr PA</b>, Pfeffer N. Disposal of fetal tissue following elective abortion: what women think J Fam Plann Reprod Health Care Published Online First: 8 September 2014] doi:10.1136/jfprhc-2013-100849 [declared at recruitment]</p>		
Patricia Lohr	Medical Director, British Pregnancy Advisory Service (BPAS)	<p>Ongoing research in a related area with plans for publication:</p> <p>Effect of Intracardiac Potassium Chloride for Feticide before Dilatation and Evacuation on Procedure Duration and</p>	Personal, non-financial, specific	Declare and participate

## Committee minutes

		Outcomes: a service evaluation  Simultaneous Administration of Mifepristone and Misoprostol for Early Medical Abortion: a service evaluation [declared at recruitment]		
Jonathan Lord	Consultant in Obstetrics & Gynaecology, Royal Cornwall Hospital	Council member (Doctors' representative & portfolio holder for quality) of British Society of Abortion Care Providers (BSACP) [declared at recruitment]	Personal, non-financial, specific	Declare and participate
Jonathan Lord	Consultant in Obstetrics & Gynaecology, Royal Cornwall Hospital	Member of clinical advisory panel for British Pregnancy Advisory Service (BPAS) [declared at recruitment]	Personal, non-financial, specific	Declare and participate
Jonathan Lord	Consultant in Obstetrics & Gynaecology, Royal Cornwall Hospital	"Quality and abortion services" Lord J. J Fam Plann Reprod Health Care 2017;43:16-17 [declared at recruitment]	Personal, non-financial, specific	Declare and participate
Jonathan Lord	Consultant in Obstetrics & Gynaecology, Royal Cornwall Hospital	Invited lecture (travel expenses paid) - "Pain relief for MVA", RSM October 2017 [declared at recruitment]	Personal, financial, specific	Declare and participate as expenses not beyond reasonable amounts
Jonathan Lord	Consultant in Obstetrics & Gynaecology, Royal Cornwall Hospital	Trainer (travel expenses paid), RCOG manual vacuum aspiration course, twice yearly with the most recent in September 2017 [declared at recruitment]	Personal, financial, specific	Declare and participate as expenses not beyond reasonable amounts
Michael Nevill	Director of Nursing, British Pregnancy Advisory service (BPAS)	I am the Director of Nursing for British Pregnancy Advisory Service [declared at recruitment]	Personal, financial,	Declare and participate
Michael Nevill	Director of Nursing, British Pregnancy Advisory	I am a member of the scientific programme committee for the Infection Prevention Society and as part of that I attend their annual conference. [declared	Personal, non-financial, non-specific	Declare and participate

## Committee minutes

	service (BPAS)	1.11.2017]		
Michael Nevill	Director of Nursing, British Pregnancy Advisory service (BPAS)	Author of opinion article. Nevill M (2017) Access to late abortion must be protected. Nursing Standard. Published 9 August 2017 [declared 1.11.2017]	Personal, non-financial, specific	Declare and participate. Guideline does not look at whether or not women should have late abortions.
Kate Randall	Lay member	No interests to declare		
Peter Taylor	Commissioning Lead, Public Health, Royal Borough of Kingston upon Thames	I have no pecuniary interests of any kind to be declared in relation to termination of pregnancy services.  I do commission, for an NHS CCG, such services and as such a direct professional interest in the outcome of this work. [declared at recruitment]	Non-personal, financial, non-specific	Declare and participate
Peter Taylor	Commissioning Lead, Public Health, Royal Borough of Kingston upon Thames	In a totally different field, that of assisted conception, I provide consultancy work for pharmaceutical companies. I acknowledge that such companies may be part of a larger group that has an arm dealing with medicines and/ or devices in use for abortion procedures and in relation to contraception products and devices. [declared at recruitment]	Personal, financial, non-specific	Declare and participate

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### 3. Presentations

The Chair introduced Angela Bennett, NGA Guideline Lead, who gave a presentation on an introduction to the NGA, guideline development, committee member roles and responsibilities and declarations of interest.

The Chair introduced Eleanor Howat, NGA Project Manager, who gave a presentation on the NGA travel policy and video conferencing.

## Committee minutes

The Chair introduced Nick Staples, NICE Guideline Commissioning Manager, who gave a presentation on an introduction to NICE guidelines.

The Chair introduced Kelly Williams, NGA Systematic Reviewer, who gave a presentation on PICOs and review protocols.

The Chair introduced Elise Hasler, NGA Information Scientist, who gave a presentation on information science in guideline development.

The Chair introduced Kelly Williams, NGA Systematic Reviewer, who gave a presentation on the evidence review process.

The Chair introduced Alex Bates, NGA Health Economist, who gave a presentation on health economics in guideline development.

The Chair introduced Emma Chambers, NICE Public Involvement Adviser, who gave a presentation on public involvement in NICE guidelines.

The Chair introduced Eleanor Howat, NGA Project Manager, who gave a presentation on file sharing using Claromentis.

The Chair introduced Angela Bennett, NGA Guideline Lead, who gave a presentation on the guideline scope overview.

The Chair introduced Alex Bates, NGA Health Economist, who gave a presentation on preliminary prioritising of health economics topics.

The Committee thanked the presenters for their presentations and contribution to the development of the guideline.

### **4. Questions and discussion**

The Chair introduced Mia Schmidt-Hansen, NGA Senior Systematic Reviewer and Kelly Williams, NGA Systematic Reviewer, who led a discussion with the committee to finalise the draft review questions.

The Committee discussed the list of planned review questions and were given the opportunity to ask questions.

### **6. Other issues**

The Committee considered the following implementation issues:

- The committee discussed the role of law and how this would impact the guideline and its implementation in Wales and Northern Ireland. NICE staff confirmed that the relevant framework was the English legal framework, as the NICE is

## Committee minutes

commissioned to make guidelines by NHS England. The GC should continue to make recommendations based on the available evidence of clinical and cost effectiveness. The wording of these recommendations will need to be structured with the relevant legal framework in mind.”

### Any other business

There was no other business to discuss. End of meeting day 1.

## Day 2

### Committee members present: (1-9)

Iain Cameron (Chair)	(Present for notes 1 – 9)
Sharon Cameron (Topic adviser)	(Present for notes 1 – 9)
Joanne Fletcher	(Present for notes 1 – 9)
Patricia Lohr	(Present for notes 1 – 9)
Jonathan Lord	(Present for notes 1 – 9)
Michael Nevill	(Present for notes 1 – 9)
Kate Randall	(Present for notes 3 – 9)
Peter Taylor	(Present for notes 1 – 9)

### In attendance:

Nick Staples	NICE Guideline Commissioning Manager	(Present for notes 1 – 4)
Alex Bates	NGA Health Economist	(Present for notes 1 - 4)
Angela Bennett	NGA Guideline Lead	(Present for notes 1 – 9)
Melanie Davies	NGA Clinical Advisor	(Present for notes 1 – 9)
Elise Hasler	NGA Information Scientist	(Present for notes 1 – 9)
Eleanor Howat	NGA Project Manager	(Present for notes 1 – 9)
Huayi Huang	NGA Systematic Reviewer	(Present for notes 1 – 9)
Laura O’Shea	NGA Systematic Reviewer	(Present for notes 1 – 9)
Mia Schmidt-Hansen	NGA Senior Systematic	(Present for notes 1 – 9)

## Committee minutes

	Reviewer	
Kelly Williams	NGA Systematic Reviewer	(Present for notes 1 – 9)

### 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to day 2 of the first meeting on Termination of Pregnancy. The Committee members and attendees introduced themselves.

The Chair informed the Committee that no apologies had been received.

The Chair outlined the objectives of the meeting, which included: finalising remaining review questions, an introduction to GRADE, drafting PICOs for 7 review questions.

#### Introductions

The committee and other attendees introduced themselves.

### 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was termination of pregnancy.

There were no new declarations of interest on day 2 of the meeting.

### 3. Presentations

The Chair introduced Kelly Williams, NGA Systematic Reviewer, who gave a presentation on GRADE – assessing the quality of evidence.

### 4. Questions and discussion

The Chair introduced Mia Schmidt-Hansen, NGA Senior Systematic Reviewer who led a discussion with the committee to finalise remaining draft review questions.

The Committee discussed the PICOs for the following review questions and were given the opportunity to ask questions.

2.12 For women who are having medical termination of pregnancy and plan to use a progestogen-only contraceptive implant or depot injection, does administration of the contraception at the same time as mifepristone influence the efficacy of the termination?

3.2 For women who have had medical termination of pregnancy, how soon

## Committee minutes

afterwards is it safe to insert an intrauterine contraceptive device?

2.3 What is the optimal antibiotic prophylaxis regimen (including no antibiotic prophylaxis as an option) for women who are having medical termination of pregnancy?

2.4 What is the optimal antibiotic prophylaxis regimen for women who are having surgical termination of pregnancy?

2.6 What is the optimal regimen for cervical priming (including no cervical priming as an option) before surgical termination of pregnancy in the first trimester?

2.7 What is the optimal regimen for cervical priming before surgical termination of pregnancy in the second trimester?

2.11 What is the optimal dose and route of administration of misoprostol after mifepristone, for inducing medical termination in the second trimester?

### **7. Any other business**

There was no other business to discuss. End of meeting day 2.

**Date of next meeting:** 23/01/2018

**Location of next meeting:** RCOG, London